German Regulator BaFin to Examine Dermapharm Transactions With Reppegather Brothers Over Million-Euro Claim
BaFin is set to review Dermapharm’s dealings with the Reppegather brothers after a claim of roughly one million euros and alleged breaches of accounting rules were reported, posing a problem for pharma billionaire Beier.